

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## SECOND INFORMATION DISCLOSURE STATEMENT

8561

Application of: SMITH et al.	Confirmation No.:
------------------------------	-------------------

Serial No.: 09/823,649 Art Unit: 1634

Filed: March 30, 2001 PTO: GOLDBERG, J.

For: HIGH TEMPERATURE Attorney Docket No: 1803-343-999

REVERSE TRANSCRIPTION USING MUTANT DNA

**POLYMERASES** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

is deci	neu mau	that to the examination of the application.				
1.	Enclosures accompanying this Second Information Disclosure Statement are:					
	1a.	A list of all patents, publications, applications, or other information submitted for consideration by the office.				
	1b.	A legible copy of:				
		Each U.S. patent application publication and U.S. and foreign patent;				
		Each publication or that portion which caused it to be listed on the PTO-1449;				
		For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;				
		all other information or portion which caused it to be listed on the PTO-1449.				
	1c.	An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.				
	1 <b>d</b> .	Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.				
2.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):  Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);				

		Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;						
		Before the mailing of the first Office action on the merits;						
		Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.						
3.		This Second Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.						
	3a.	☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.						
	3b.	<ul> <li>☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:</li> <li>☐ enclosed</li> <li>☐ to be charged to Pennie &amp; Edmonds LLP Deposit Account No. 16-1150 (1803-</li> </ul>						
		343-999).						
		(Item 3b to be checked if any reference known for more than 3 months)						
4.		This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.						
		The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:  — enclosed.  — to be charged to Pennie & Edmonds LLP Deposit Account No. 16-1150.						
	The Ce	Certification Statement in Item 5 below is applicable.						
5.		Certification Statement (applicable if Item 3a or Item 4 is checked)						
	5a.	In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.						
	5b.	In accordance with 37 C.F.R. §1.97(e)(2), it is certified that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was known by any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
6.		This application is a continuation application under 37 C.F.R. §1.60 or §1.53(b) or (d).						
	6a.	☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.						
	6b.	Copies of publications listed on Form PTO-1449 from prior application Serial No., filed on, of which this application claims priority under 35						

U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d). 6c. Copies of the publications listed on Form PTO-1449 were not previously cited in , filed on , and are provided herewith. prior application Serial No. This is a Supplemental Information Disclosure Statement. (Check Item 7a) 7. 7a. This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on 8. In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is: satisfied because all non-English language publications were cited on the 8a. enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office. 8b. set forth in the application. enclosed as an attachment hereto. 8c. 9.  $\boxtimes$ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Pennie & Edmonds LLP Deposit Account No. 16-1150 (order no. 1803-343-999).  $\boxtimes$ 10. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h). Respectfully submitted. June 30, 2003 Date: Rahul Pathak (Reg. No.) For: Nikolaos C. George (39,201) PENNIE & EDMONDS LLP 3300 Hillview Avenue Palo Alto, CA 94304

(650) 493-4935

		<i>`O</i> `}		• .					Silect I	JI 1
	3 6	3003 E	-			ATTY DOCKET NO.		APPLICATIO	N NO	
70N 3 0 5003					1803-343-999		09/823,649			
SECOND	LIST	OF REFERENCES ( Use several sheets if n	CITED BY	APPLIC	ANT	APPLICANT				
	Te	Use several sheets if n	ecessary)			SMITH et al.				
				FILING DATE		GROUP				
						March 30, 2001		1624		
			U.S. P	ATENT D	OCUM	ENTS				
*EXAMINER								FILING DATE SUBCLASS IF APPROPRIATE		
INITIAL	<del>  -</del>	DOCUMENT NUMBER	DATE	<del>                                     </del>	N	AME	CLASS	SUBCLASS	IF APPRO	PRIATE
				<u> </u>			1			
	<b> </b>									
				1						
				<u> </u>			<u> </u>			
									1905	
					<del>-</del> -					
			FOREIGN	N PATENT			T		T	
	<u></u>	DOCUMENT NUMBER	DATE		COL	JNTRY	CLASS	SUBCLASS	TRANSI YES	NO
		OTHER REFERE								
	AF	TSE, William T., et al., "R Gene (1990) 88:293-296			irect Am	plification of Cellular	RNA Tran	scripts by Ta	q Polymer	ase,"
	AG	BECKMAN, Robert A., et al., "On the Fidelity of DNA Replication: Manganese Mutagenesis in Vitro," Biochemistry (1985)								
	AH	24:5810-5817 (0006-2960/85).  LEUNG, David W., et al., "A Method for Random Mutagenesis of a Defined DNA Segment Using a Modified Polymerase Chain Reaction," Technique (1989) Vol. 1, 1:11-15 (1043-4658/89).								
	AI	BROWN, D.M., "Basic F Academic Press, (1974) V	Principles in N	ucleic Acid C	hemistry	- Chemical Reactions	of Polynuc	cleotides and	Nucleic A	cids,"
EXAMINER						CONSIDERED				
		reference considered, whether y of this form with next commu			ce with M	PEP 609; Draw line thro	ugh citation	if not in confo	rmance and	not